Close Menu

NEW YORK – Agilent Technologies said today that it has received CE-IVD marking in Europe for its PD-L1 IHC 22C3 assay for head and neck squamous cell carcinoma (HNSCC), a companion diagnostic in combination with Merck's anti-PD-1 immunotherapy pembrolizumab (Keytruda). 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.